Share on StockTwits

A number of firms have modified their ratings and price targets on shares of Endocyte (NASDAQ: ECYT) recently:

  • Endocyte was downgraded by analysts at Piper Jaffray from an “overweight” rating to a “neutral” rating. They now have a $13.50 price target on the stock.
  • Endocyte was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $36.00.
  • Endocyte had its price target lowered by analysts at Brean Capital from $41.00 to $22.00. They now have a “buy” rating on the stock.
  • Endocyte had its price target lowered by analysts at RBC Capital from $46.00 to $20.00. They now have an “outperform” rating on the stock.
  • Endocyte had its price target lowered by analysts at Chardan Capital from $43.00 to $26.00. They now have a “buy” rating on the stock.

Shares of Endocyte, Inc. (NASDAQ:ECYT) opened at 6.99 on Tuesday. Endocyte, Inc. has a 52 week low of $6.50 and a 52 week high of $33.70. The stock’s 50-day moving average is $19.62 and its 200-day moving average is $13.8. The company’s market cap is $253.0 million.

Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.